RxDoctor Payments Data

Lily Stern, MD

Advanced Heart Failure and Transplant Cardiology · Beverly Hills, CANPI 1144682410

Payments from drug & device makers

$31,793in general payments, 2019–2025

Across 38 payments — averaging $836.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$14K
  • Bridgebio Pharma, Inc.$9K
  • Alnylam Pharmaceuticals Inc.$7K
  • Abiomed$428
  • Abbott$328
  • AstraZeneca$238
  • plus $256 from 2 others

What the payments were for

  • Consulting fees$20,63565%
  • Speaking & faculty fees$7,28623%
  • Travel & lodging$1,5345%
  • Food & beverage$2,3387%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,793 in reported general payments places this provider in the 45th percentile of 111 advanced heart failure and transplant cardiology providers in California.

See all advanced heart failure and transplant cardiology providers in California

Medicare billing

Part B allowed, 2024
$95,304
Medicare patients
283
Services billed
884

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis22$567,596
JardianceEmpagliflozin24$21,778
EliquisApixaban25$20,479
EntrestoSacubitril/Valsartan13$19,388
Valganciclovir Hcl41$11,238
Rosuvastatin Calcium88$1,664
Nano 2nd Gen Pen NeedlePen Needle, Diabetic22$1,077
Clotrimazole30$893
Valsartan21$717
Ezetimibe19$462
Metoprolol Succinate32$453
Amlodipine Besylate49$402
Atorvastatin Calcium59$326
Pravastatin Sodium54$322
Prednisone32$321

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$14,404$588,07447 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 111 advanced heart failure and transplant cardiology providers in California.

Other advanced heart failure and transplant cardiology in Beverly Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →